Close
Help




JOURNAL

Clinical Medicine Insights: Oncology

492,299 Journal Article Views | Journal Analytics

Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab

Submit a Paper



Publication Date: 16 Aug 2012

Type: Review

Journal: Clinical Medicine Insights: Oncology

Citation: Clinical Medicine Insights: Oncology 2012:6 287-303

doi: 10.4137/CMO.S8511

Abstract

Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.


Downloads

PDF  (1.18 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Clinical Medicine Insights: Oncology
I have been very pleased with the attention and dedication provided to my paper.  It was very well organized and informative and all the information that I needed during the process of publication was readily available.  The review process was quick and I am very satisfied with the service provided by Libertas.  Thank you for your service.
Dr Henrique Lopes (Barretos Cancer Hospital, Barretos, SP, Brazil)
More Testimonials

Quick Links


New article and journal news notification services